Navigation Links
ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
Date:9/6/2007

LEUVEN, Belgium and LUND, Sweden, September 7 /PRNewswire/ --

- Decision Taken to Advance Novel, Long-Acting Anticoagulant Into Phase II Clinical Development

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular disease, and co-development partner, BioInvent International (Nordic Exchange: BINV), announce today that they have successfully completed enrollment and initial follow-up of all volunteers in the first Phase I trial of TB-402, which is being developed for the prevention of venous thromboembolic disorders (VTE - blood clots).

TB-402 is a recombinant human monoclonal antibody that targets factor VIII, a component of the coagulation cascade. This antibody is a promising novel anticoagulant agent particularly because it only partially inhibits factor VIII activity even when administrated in very high doses. This may potentially decrease the risk of undesirable bleedings and the need for monitoring, which are the main concerns associated with anticoagulants currently on the market.

The trial, performed in Denmark, was a randomized, single-dose, placebo-controlled, dose-escalation trial in healthy male volunteers. 56 volunteers were enrolled into the trial, including both younger age volunteers (18-45) and older age volunteers (55-76).

Preliminary results of the trial showed that TB-402 met both the primary (safety and tolerability) and secondary (pharmacokinetic and pharmacodynamic) endpoints. The drug was well tolerated and the study showed that TB-402's prolonged half-life will allow for single-dose treatment in orthopaedic surgery patients and/or once-a-month administration for long-term stroke prevention in atrial fibrillation (AF), as opposed to daily treatment with current anticoagulants. Importantly, the findings confirm that TB-402 achieves only partial inhibition of factor VIII activity without the undesired effect of total factor VIII inactivation. Final data analysis of the first Ph
'/>"/>

SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle, WARF announce partnership to lure stem cell companies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... Mass. , May 20, 2015  Haemonetics Corporation ... Concannon , President & CEO, will present at The ... York on June 1 st , 2015 ... may access Mr. Concannon,s presentation live via webcast at: ... Haemonetics (NYSE: HAE ) is a global ...
(Date:5/20/2015)... May 20, 2015  Resolution Bioscience announced today the ... ALK TM , a blood-based liquid biopsy for an ... carcinoma (NSCLC), the most common form of this cancer. ... guide patients to personalized therapies and direct them into ... The Department of Health, the CLIA authority in ...
(Date:5/20/2015)... Carolina , 20. Mai 2015 ... für klinische Logistik (Clinical Logistics Organization/CLO) ... Geschäftsjahr 2014, das am 31. Dezember ... Unternehmen hat die Marktentwicklung übertroffen und ... - http://photos.prnewswire.com/prnh/20110930/NY78064LOGO ...
(Date:5/20/2015)... (PRWEB) May 20, 2015 The ... based not-for-profit organization, is pleased to announce they are ... Trials Day. These donations represent the effort and commitment ... at the GGI partner sites in 2014. , ... the greater good of clinical trial participation, GGI supports ...
Breaking Biology Technology:Resolution Bioscience Receives CLIA Certification for its Diagnostic Laboratory and Launches CLIA-Certified Liquid Biopsy for Lung Cancer 2Marken schließt Ergebnisse für das Geschäftsjahr 2014 ab 2The Greater Gift Initiative Donates over 10,000 Vaccines in Honor of International Clinical Trials Day 2
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/8/2015)... Synaptics Inc. (NASDAQ: SYNA ), the leading ... the executive management team will present at the following investor ... Telecom Conference Date: May 18, 2015 Time: 10:40am ... Cowen and Company Technology, Media & ... The New York Palace Hotel, New York, NY ...
(Date:5/6/2015)... 2015 LifeBEAM, a developer of bio-sensing technology, ... today that they will expand their partnership in bio-sensing ... cycling helmet and the first joint project between the ... in order to give cyclists more style choices and ... and Lazer announced their plan to release a new ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... of the 1962 Nobel Prize with Francis Crick and Maurice ... DNA, will present "Curing Incurable Cancer" and attend other events ... the James Graham Brown Cancer Center at the University of ... 5, at the Brown Theater, 315 W. Broadway, Louisville. Admission ...
... early stages of a major cause of failure in joint ... avoid additional surgery. More than 1.5 million total joint replacement ... is 90 per cent, almost 10 per cent of implants ... journal Molecular Pharmaceutics . Dong Wang and colleagues ...
... do not rely on oxygen may have played an important ... to a theory that UChicago researcher Albert Colman is testing ... Siberia. He has found that bacteria at the site ... that scientists must take into account as they attempt to ...
Cached Biology News:UofL hosts address by Nobel Laureate, DNA structure co-discoverer James Watson 2Cold case: Siberian hot springs reveal ancient ecology 2Cold case: Siberian hot springs reveal ancient ecology 3
... immunoaffinity purified antibody detects an ~185 kDa ... of ErbB-2 phosphorylated at tyrosine 1248 on ... been cross adsorbed against the non-phosphorylated peptide ... non-phosphorylated form of the protein. In ...
Mouse monoclonal [4A2.2] to SLC6A4 ( Abpromise for all tested applications). entrezGeneID: 6532 SwissProtID: P31645...
...
... The complete SSCP kit provides all ... mutation detection by single-stranded conformation polymorphism analysis ... system. The kit includes a cooling finger ... (not provided), 2 sets of 20 cm ...
Biology Products: